On March 6, 2026, Durso Jerome Benedict, the director, President, and CEO of Altimmune (NASDAQ: ALT), purchased 20,000 shares of the company's common stock at about $3.54 per share. This acquisition increased his total holdings to 32,500 shares. This move reflects confidence in the company's future, especially given its strategic focus on liver disease treatments.
Altimmune recently held a year-end 2025 earnings call, where executives discussed their strategic focus and future plans. They are preparing for a pivotal Phase 3 program for pemvidutide, a treatment targeting metabolic dysfunction-associated steatohepatitis (MASH). This aligns with Durso's emphasis on addressing significant unmet needs in liver diseases, as highlighted by the company's exclusive focus on this area.
During the earnings call, CEO Jerry Durso highlighted pemvidutide's unique "balanced one-to-one agonism of glucagon and GLP-1." This approach could differentiate Altimmune in the treatment landscape. The glucagon component may help reduce liver fat, inflammation, and fibrotic activity, while the GLP-1 component could aid in weight loss and appetite suppression. This innovative approach is part of Altimmune's proprietary "uPort" structure.
The stock for ALT is currently priced at $3.54, experiencing a slight increase of 0.99%, or $0.035. Throughout the day, the stock fluctuated between $3.41 and $3.74. Over the past year, ALT reached a high of $7.73 and a low of $2.9. The company's market capitalization is approximately $312.4 million, with a trading volume of 5,385,353 shares.
